At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TPST Tempest Therapeutics Inc.
Trading 11-04 13:02:33 EST
0.9329
+0.0235
+2.58%
High0.9388Low0.8637Vol1.36M
Open0.8955D1 Closing0.9094Amplitude8.26%
Mkt Cap23.52MTradable Cap20.06MTotal Shares25.21M
T/O1.22MT/O Rate6.34%Tradable Shares21.51M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Tempest Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Reuters  ·  11-04 23:48
Tempest Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Allakos (ALLK) and Tempest Therapeutics (TPST)
TIPRANKS  ·  10-11
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Allakos (ALLK) and Tempest Therapeutics (TPST)
Scotiabank Sticks to Their Buy Rating for Tempest Therapeutics (TPST)
TIPRANKS  ·  10-11
Scotiabank Sticks to Their Buy Rating for Tempest Therapeutics (TPST)
Tempest Therapeutics Shares up 12.6% at $1.74 After Agreement to Test Its Liver Cancer Drug With Roche's Therapy in Pivotal Study
THOMSON REUTERS  ·  10-10
Tempest Therapeutics Shares up 12.6% at $1.74 After Agreement to Test Its Liver Cancer Drug With Roche's Therapy in Pivotal Study
BUZZ-Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study
Reuters  ·  10-10
BUZZ-Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study
Traders Digest Consumer Inflation Measure as US Equity Futures Drop Pre-Bell
MT Newswires Live  ·  10-10
Traders Digest Consumer Inflation Measure as US Equity Futures Drop Pre-Bell
Tempest Therapeutics to Advance Liver Cancer Drug to Phase 3 Trial with Roche; Shares Jump Pre-Bell
MT Newswires Live  ·  10-10
Tempest Therapeutics to Advance Liver Cancer Drug to Phase 3 Trial with Roche; Shares Jump Pre-Bell
Roche collaboration for lead asset boosts Tempest
seekingalpha  ·  10-10
Roche collaboration for lead asset boosts Tempest
Tempest Therapeutics Shares up 29% at $1.74 Premarket After Agreement to Test Its Liver Cancer Drug With Roche's Therapy in Pivotal Study
THOMSON REUTERS  ·  10-10
Tempest Therapeutics Shares up 29% at $1.74 Premarket After Agreement to Test Its Liver Cancer Drug With Roche's Therapy in Pivotal Study
Tempest Therapeutics Extends Limited Duration Stockholder Rights Plan; Shares Rise Premarket
MT Newswires Live  ·  10-10
Tempest Therapeutics Extends Limited Duration Stockholder Rights Plan; Shares Rise Premarket
BRIEF-Tempest Announces Agreement With Roche To Support Advancement Of Amezalpat Combination Therapy Into First-Line Hepatocellular Carcinoma Pivotal Trial
Reuters  ·  10-10
BRIEF-Tempest Announces Agreement With Roche To Support Advancement Of Amezalpat Combination Therapy Into First-Line Hepatocellular Carcinoma Pivotal Trial
Tempest Therapeutics Inc - Phase 3 Study to Start in Q1 2025
THOMSON REUTERS  ·  10-10
Tempest Therapeutics Inc - Phase 3 Study to Start in Q1 2025
Tempest Announces Agreement With Roche to Support Advancement of Amezalpat Combination Therapy Into First-Line Hepatocellular Carcinoma Pivotal Trial
THOMSON REUTERS  ·  10-10
Tempest Announces Agreement With Roche to Support Advancement of Amezalpat Combination Therapy Into First-Line Hepatocellular Carcinoma Pivotal Trial
Tempest Therapeutics Inc - Rights Plan to Expire After 2025 Annual Meeting Unless Approved
THOMSON REUTERS  ·  10-10
Tempest Therapeutics Inc - Rights Plan to Expire After 2025 Annual Meeting Unless Approved
Tempest Extends Limited Duration Stockholder Rights Plan
THOMSON REUTERS  ·  10-10
Tempest Extends Limited Duration Stockholder Rights Plan
Tempest Extends Limited Duration Stockholder Rights Plan
GlobeNewswire  ·  10-10
Tempest Extends Limited Duration Stockholder Rights Plan
BRIEF-Tempest Appoints Sheldon Mullins As Vice President, Regulatory Affairs
Reuters  ·  09-18
BRIEF-Tempest Appoints Sheldon Mullins As Vice President, Regulatory Affairs
Tempest Further Strengthens Leadership Team With Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
THOMSON REUTERS  ·  09-18
Tempest Further Strengthens Leadership Team With Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
Press Release: Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
Dow Jones  ·  09-18
Press Release: Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
THOMSON REUTERS  ·  08-21
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance

Introduction

Company Name.
Tempest Therapeutics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Issue price:
--